一项评估完全植入式人工耳蜗(TICI)系统在成人中的临床获益、性能和安全性的关键研究 (ELEVATE)
一项关键性、上市前、前瞻性、介入性、多中心研究,旨在评估TI1132植入物在患有感音神经性听力损失的成年人群中的临床获益、性能和安全性
This pivotal study examines the clinical efficacy and safety of an investigational totally implantable cochlear implant (TICI) system. The system includes a microphone placed under the skin to detect speech and sound from the environment, providing the option to hear without any visible external parts. This study will involve adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). Participants will complete hearing tests and questionnaires to evaluate how well the system works and how it affects their daily life.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Colorado
-
Englewood、Colorado、美国、80113
- Rocky Mountain Ear Center
-
-
Florida
-
Miami、Florida、美国、33136
- University of Miami School of Medicine
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa
-
-
Michigan
-
Novi、Michigan、美国、48374
- Michigan Ear Institute
-
-
Minnesota
-
Rochester、Minnesota、美国、55902
- Mayo Foundation Rochester
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- Midwest Ear Institute
-
St Louis、Missouri、美国、63108
- Washington University School of Medicine
-
-
New York
-
New York、New York、美国、10017
- NYU Langone Health
-
-
Ohio
-
Beachwood、Ohio、美国、44122
- University Hospitals Cleveland Medical Centre
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73120
- Hearts for Hearing Foundation
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- University of Utah Hospitals and Clinics
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Individuals aged 18 years and older at time of consent.
- Clinically established sensorineural hearing loss (SNHL) defined by a four frequency (500, 1000, 2000, 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥70 dB HL in the ear to be implanted.
- Compromised functional hearing in the aided condition defined as ≤40% correct on a word recognition test in the ear to be implanted.
- Clinically established SNHL defined by a four-frequency (500, 1000, 2000 & 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥30 dB HL in the contralateral ear.
- Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator.
- Direct access to a compatible Smart Phone.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
- Candidates with single-sided deafness as determined by the investigator.
- Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
- Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
- Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
- Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
- Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
- Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
- Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
- Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted.
- Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
- Pre-existing skin condition that could jeopardize wound healing as judged by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes.
- Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
- Additional disabilities that may affect the participant's participation or safety during the clinical investigation.
- Unable or unwilling to comply with all requirements of the clinical investigation, as determined by the investigator.
- Pregnant or breastfeeding women.
- Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
- Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Totally Implantable Cochlear Implant System
Participants will be implanted with the TI1132 implant |
Totally Implantable Cochlear Implant System |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Speech recognition performance in quiet
大体时间:Preimplantation to 6-months post-activation
|
Percent correct scores in word recognition score from pre-implantation to post-implantation. |
Preimplantation to 6-months post-activation
|
|
Incidence of adverse events and device deficiencies
大体时间:Implantation to 6- and 12-months post-activation
|
Frequency and severity of device and procedure-related adverse events, including device deficiencies. |
Implantation to 6- and 12-months post-activation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Speech, Spatial and Qualities of Hearing questionnaire (SSQ-12)
大体时间:Preimplantation to 6- and 12-months post-activation
|
Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability). |
Preimplantation to 6- and 12-months post-activation
|
|
Speech recognition performance in noise
大体时间:Preimplantation to 6- and 12-months post-activation
|
Percent correct sentence score from preimplantation to 6- and 12-months post-activation. |
Preimplantation to 6- and 12-months post-activation
|
|
Speech recognition performance in quiet
大体时间:Preimplantation to 12-months post-activation
|
Percent correct word recognition score in quiet from pre-implantation to post-implantation. |
Preimplantation to 12-months post-activation
|
|
Cochlear Implant Quality of Life Profile (CIQOL-35)
大体时间:Preimplantation to 6- and 12-months post-activation
|
Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health. |
Preimplantation to 6- and 12-months post-activation
|
|
Health Utilities Index (HUI 2/3)
大体时间:Preimplantation to 6- and 12-months post-activation
|
Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health". |
Preimplantation to 6- and 12-months post-activation
|
|
Living with Cochlear Implants Questionnaire (LivCI)
大体时间:Preimplantation to 6- and 12-months post-activation
|
Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial & Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management & Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report. |
Preimplantation to 6- and 12-months post-activation
|
|
Patient Satisfaction Survey
大体时间:From 6 to 12 months post-activation
|
Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system. |
From 6 to 12 months post-activation
|
合作者和调查者
赞助
调查人员
- 首席研究员:Craig Buchman、University of Utah
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.